A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

ClinicalTrials.gov ID: NCT05877599

Public ClinicalTrials.gov record NCT05877599. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

Study identification

NCT ID: NCT05877599
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: AstraZeneca; Industry
Enrollment: 45 participants

Conditions and interventions

Conditions

Interventions

NT-175 Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 11, 2023
Primary completion: Jul 30, 2029
Completion: Jul 30, 2029
Last update posted: Aug 31, 2026

2023 – 2029

United States locations

U.S. sites: 20
U.S. states: 12
U.S. cities: 19

Facility	City	State	ZIP	Site status
Research Site	Gilbert	Arizona	85234	Recruiting
Research Site	Duarte	California	91010	Not yet recruiting
Research Site	Los Angeles	California	90095	Not yet recruiting
Research Site	Newport Beach	California	92663	Recruiting
Research Site	Santa Monica	California	90404	Recruiting
Research Site	Jacksonville	Florida	32224	Recruiting
Research Site	Miami	Florida	33136	Withdrawn
Research Site	Tampa	Florida	33612	Withdrawn
Research Site	Boston	Massachusetts	02115	Recruiting
Research Site	Boston	Massachusetts	02215	Not yet recruiting
Research Site	New Brunswick	New Jersey	08901	Recruiting
Research Site	New York	New York	10065	Not yet recruiting
Research Site	Charlotte	North Carolina	28204	Withdrawn
Research Site	Winston-Salem	North Carolina	27103	Withdrawn
Research Site	Portland	Oregon	97213	Recruiting
Research Site	Pittsburgh	Pennsylvania	15232	Recruiting
Research Site	Nashville	Tennessee	37203	Recruiting
Research Site	Houston	Texas	77030	Not yet recruiting
Research Site	Round Rock	Texas	78665	Recruiting
Research Site	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05877599, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 31, 2026 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05877599 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →